Mylan (MYL), the generic pharmaceuticals company that is now the object of a hostile takeover bid from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), reported its senior executives’ compensation at the end of last week. The report is interesting in the light of the exchange between the two companies over the takeover bid. Mylan chairman Robert Coury’s rejection of Teva’s bid cast aspersions on Teva’s corporate culture… [READ MORE]
Published by Globes [online], Israel business news – www.globes-online.com
